XOMA (NASDAQ:XOMA)‘s stock had its “hold” rating reissued by equities researchers at Cowen in a research note issued to investors on Thursday.

Several other research analysts have also recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of XOMA in a report on Wednesday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price target on shares of XOMA in a report on Friday, September 21st. Zacks Investment Research cut shares of XOMA from a “buy” rating to a “hold” rating in a report on Saturday, July 21st. ValuEngine cut shares of XOMA from a “hold” rating to a “sell” rating in a report on Friday, September 7th. Finally, S&P Equity Research decreased their price target on shares of XOMA from $18.74 to $16.26 in a report on Tuesday, August 14th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. XOMA has an average rating of “Hold” and an average target price of $28.07.

Shares of XOMA stock traded down $0.37 during trading on Thursday, hitting $14.39. The stock had a trading volume of 88,924 shares, compared to its average volume of 105,124. The stock has a market cap of $116.41 million, a P/E ratio of 14.68 and a beta of 2.75. XOMA has a 12 month low of $11.88 and a 12 month high of $37.25. The company has a debt-to-equity ratio of 3.06, a quick ratio of 12.46 and a current ratio of 12.46.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.40). The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.83 million. XOMA had a negative return on equity of 214.93% and a negative net margin of 129.85%. Sell-side analysts predict that XOMA will post -1.14 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. Allianz Asset Management GmbH increased its stake in XOMA by 32.7% in the first quarter. Allianz Asset Management GmbH now owns 12,245 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 3,020 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its stake in XOMA by 57.6% in the second quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock valued at $420,000 after acquiring an additional 7,349 shares during the last quarter. ClariVest Asset Management LLC increased its stake in XOMA by 25.0% in the second quarter. ClariVest Asset Management LLC now owns 23,500 shares of the biotechnology company’s stock valued at $490,000 after acquiring an additional 4,700 shares during the last quarter. Alps Advisors Inc. increased its stake in XOMA by 82.6% in the second quarter. Alps Advisors Inc. now owns 19,946 shares of the biotechnology company’s stock valued at $542,000 after acquiring an additional 9,024 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in XOMA in the second quarter valued at $568,000. 43.49% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.